Key Points
• MM cell lines and primary MM cells can be engrafted and grown in vivo in Casper zebrafish larvaes.
• Zebrafish MM in vivo xenograft model can be used as a pre-treatment drug sensitivity prediction platform for MM patients.
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Introduction
The gene expression profile and other genomic data have so far failed to predict individual responses to therapy 1, 2 . Newer murine multiple myeloma (MM) models that recapitulate human disease to some extent have been developed but their ability to predict clinical responses have remained limited [2] [3] [4] [5] . The limitations of murine tumor xenografts model includes the need for human fetal bone fragments to support the tumor growth, the low efficiency resulting in the generation of a limited number of tumorbearing mice, and a two month lag period for tumor growth. These limitations highlight the need for a new model that allows efficient and rapid growth of human MM cells in an animal model applicable for pre-treatment drug response prediction and screening. Here, we describe a novel zebrafish model that supports the growth of both MM cell lines and primary MM cells and could provide an efficient, rapid and inexpensive platform for drug screening and studying the biology of MM.
Methods

Animal Care and Handling
The Casper strain of zebrafish (Danio rerio) were raised at 28.5ºC in E3 buffer with cycles of 14/10 hours light/darkness cycles and fed in accordance with guidelines established by the Committee on the Ethics of Animal Experiments of Children's Hospital Boston (No. 09-09-1540R).
MM cell lines and Patient cell Microinjection
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From All MM cell lines utilized and their culture conditions have been previously described 6 . Primary plasma cells from MM patients were obtained after informed consent and isolated as described previously 7 . The CM-DIL labeled MM cell lines and primary CD138+ MM cells were washed in PBS, re-suspended in Matrigel at 10,000 cells/µl. Thirty-six hour post fertilization (hpf) Casper embryos were dechorionated with 1 mg/ml of pronase for 5-10 minutes. Forty-eight to ninety-six hpf embryos were anesthetized by placement in 0.04 mg/ml Ethyl 3-aminobenzoate methanesulfonate tricaine. The MM cells (100 cells in 10nl, 5-20 nl injection volume/embryo) were injected into the perivitelline space with a pneumatic Picopump injector using glass micro-injection needles.
Drug Treatment and Efficiency Evaluation
We evaluated the tumor xenografts by fluorescence microscopy 24 hours post-injection (hpi). Those embryos with red fluorescence at the injection site were moved to 24-well uncoated plates (1 embryo/well) and freshly prepared E3 medium containing drugs or solvent was added to each well according to the experimental group. Stock solutions of the drugs to be tested were prepared, as previously described
and then diluted at least at 1:1000 with E3 medium before adding to embryos in the 24-well plates. Fresh drug containing E3 medium was replaced daily. We evaluated tumor growth and fish survival at 24, 48
and 72 hours post treatment (hpt) by fluorescence microscopy. We measured the area and density of fluorescence on photomicrographs with ImageJ software and estimated tumor xenografts volume in control and drug treated animals.
Results and Discussion
Casper zebrafish in vivo MM xenografts model
We utilized transparent Casper zebrafish early stage embryos (48 hpf) as they allow in vivo observation of growth changes in fluorescent-labeled myeloma cell xenografts ( Figure 1A ) 11 and are immune deficient 12, 13 allowing the growth of human cells. We first utilized MM1S and MM1R MM cell lines to demonstrate MM cell growth in zebrafish embryos and determine whether addition of anti-MM drugs to embryo water would inhibit cell growth. As seen in Figure 1B , CM-Dil-labeled MM cells injected in perivitelline area of Casper zebrafish could be observed by fluorescence microscopy 24 hpi and over 80% of larvae retained injected MM cells for 9 days, providing an adequate window for drug screening. These xenografts were confirmed by immunofluorescence microscopy ( Figure 1C ). To further evaluate the utility of the xenograft model for drug screening, we chose 2 first line anti-MM drugs, bortezomib (10nM) and lenalidomide (2μM), and 4 novel agents, AZD6244 (400nM), 17-AAG (800nM), AS703026 (800nM) and rapamycin (40nM), which have been tested in MM. We used 4 MM cell lines, MM1S, MM1R, OPM1 and RPMI8226, for this evaluation. MM1S is sensitive to bortezomib, lenalidomide and dexamethasone (>60% larvae showing a response); and relatively sensitive to all other 4 agents (30% to 60% of tested fish had a response) ( Figure 2C ). Relative sensitivity and resistance of other cell lines to the standard agents as well as investigational agents were shown in Figure 2D .
Next, we assessed the effect of these novel agents on primary MM cells from 2 newly diagnosed and 4 relapsed/refractory MM patients. Efficiency of engraftment of primary cells is similar to cell lines, which is about 80%. We treated embryos engrafted with patient cells with these agents and observed that both newly diagnosed patients responded to bortezomib and lenalidomide with >50% reduction at 72 hpt
(Figure 2 E-F and data not shown). We observed that cells from those patients with resistance to
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We here describe a zebrafish embryo xenograft model that supports the growth of MM cell lines and primary patient cells and can be used to predict drug sensitivity and potentially utilized for pre-clinical drug screening. The advantages of the system are ability to use patient cells, requirement for small number of MM cells, less variability between animals, ability to perform medium throughput in vivo drug screening using primary MM patient cells and short latency that may permit quick screening in real time.
The limitations of this model include the smaller number of embryos that could be injected at single sitting, growth within a unique microenvironment, growth at a lower temperature required by fish and undervaluation of the influence on drug resistance induced by bone marrow microenvironment. The variability between different fish can be observed but can be compensated by injecting large number of larvae. The ability of zebrafish to support MM cell growth may provide insight into unique microenvironment in the fish that supports MM cell growth, even though it may not have all the characteristics of the actual bone marrow microenvironment. This easy, quick and economical model overcomes many of the limitations of murine xenograft models and should be further evaluated as a tool to screen and predict drug sensitivity in MM.
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